Physician Assistant Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Kasey Brundidge

Physician Assistant, Medical Ada, OK Physician Assistant

NPI 1669676961 CMS profile 10684414

1201 Arlington St, Ste F, Ada, OK 74820

Open in the dashboard

General payments

$4,165

173 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Kasey Brundidge of Ada, OK is reported in the CMS Open Payments database as having received $4,165 across 173 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 86th percentile of Physician Assistant, Medical profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $2,167 32
2024 General $390 24
2023 General $368 24
2022 General $388 26
2021 General $852 67

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Kasey Brundidge
  • Physician Assistant, Medical median
  • Middle half of Physician Assistant, Medical
  • National median

In program year 2025, general payments to Kasey Brundidge were reported at $2,167. Among 16,675 Physician Assistant, Medical profiles paid that year, the median was $214 and the middle half received between $62 and $755.

Show as a table
Year Kasey Brundidge Physician Assistant, Medical median Middle half National median
2019 $0 $61 $19–$193 $163
2020 $0 $20 $14–$64 $114
2021 $852 $156 $41–$563 $132
2022 $388 $185 $55–$649 $149
2023 $368 $199 $58–$717 $160
2024 $390 $206 $62–$740 $164
2025 $2,167 $214 $62–$755 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. Boston Scientific Corporation $1,746 8 payments
  2. Novo Nordisk Inc $776 55 payments
  3. Lilly USA, LLC $264 22 payments
  4. AbbVie, Inc. $247 19 payments
  5. AstraZeneca Pharmaceuticals LP $230 14 payments
  6. Takeda Pharmaceuticals U.S.A., Inc. $227 13 payments
  7. Pfizer Inc. $190 12 payments
  8. Corcept Therapeutics $115 6 payments
  9. Allergan Inc. $55 3 payments
  10. Merck Sharp & Dohme Corporation $50 4 payments
  11. Other $264 17 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $2,691 166 payments
  2. Travel and Lodging $1,462 6 payments
  3. Education $12 1 payment
Products named General payments · program years 2021–2025
  1. FARAPULSE $1,746 8 payments
  2. RYBELSUS $641 36 payments
  3. Ozempic $610 34 payments
  4. TRINTELLIX $227 13 payments
  5. TRULICITY $204 15 payments
  6. VRAYLAR $199 16 payments
  7. COLOGUARD DNA CAPTURE REAGENTS $156 10 payments
  8. FARXIGA $115 7 payments
  9. Korlym $115 6 payments
  10. AIRSUPRA $102 6 payments
  11. Other $1,047 87 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 131 drugs

Part D claims

5,253

Median for Physician Assistant: 241

Drug cost

$593,143

Median for Physician Assistant: $4,110

Branded share of claims

20.2%

Median for Physician Assistant: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Ozempic Semaglutide Brand 95 $107,009
Epidiolex Cannabidiol (Cbd) Brand 17 $58,361
Trintellix Vortioxetine Hydrobromide Brand 107 $51,226
Farxiga Dapagliflozin Propanediol Brand 55 $44,866
Vraylar Cariprazine Hcl Brand 22 $33,763
Eliquis Apixaban Brand 37 $31,394
Mounjaro Tirzepatide Brand 24 $29,576
Trulicity Dulaglutide Brand 25 $26,930
Januvia Sitagliptin Phosphate Brand 35 $25,142
Tresiba Flextouch U-200 Insulin Degludec Brand 11 $14,724

The 10 drugs with the highest cost, of 131 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 114,276 Part D prescribers listed as Physician Assistant; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 41 billing codes

Paid by Medicare

$141,881

Of which drugs: $251

Medicare patients

430

Average age 68

Services billed

3,644

281 women, 149 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 48%
Diabetes 36%
Depression 32%
Ischemic heart disease 26%
COPD 21%
Chronic kidney disease 20%
Heart failure 18%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, triamcinolone acetonide, not otherwise specified, 10 mg J3301 Office 12 27 $18
Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg J3420 Office 12 18 $16
Injection, dexamethasone sodium phosphate, 1 mg J1100 Office 35 184 $16
Injection, ceftriaxone sodium, per 250 mg J0696 Office 11 39 $14
Injection, methylprednisolone acetate, 1 mg J1010 Office 15 18 $2

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 13 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
AIRSUPRA
  • AstraZeneca Pharmaceuticals LP $84
$84 — —
RYBELSUS
  • Novo Nordisk Inc $64
$64 — —
Ozempic
  • Novo Nordisk Inc $64
$64 95 —
TRINTELLIX
  • Takeda Pharmaceuticals U.S.A., Inc. $54
$54 107 —
Auvelity
  • Axsome Therapeutics, Inc. $23
$23 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 13 in the dashboard with a free account

Records

173 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Physician Assistant, Medical in Oklahoma

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record